Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Omnitrope

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
A biosimilar is defined by the European Medicines Agency as a biological medicine that is similar to another biological medicine… Expand
  • figure 1
  • figure 2
  • table 1
Is this relevant?
2017
2017
PurposeTo report the long-term effectiveness and safety of the recombinant human growth hormone Omnitrope®, a somatropin… Expand
  • table 1
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
Review
2017
Review
2017
  • Paul Saenger
  • Drug design, development and therapy
  • 2017
  • Corpus ID: 6818718
Recombinant human growth hormone (rhGH) has been in clinical use for more than 30 years. With the expiration of patent… Expand
  • figure 1
Is this relevant?
Review
2017
Review
2017
Safety concerns for recombinant human growth hormone (rhGH) treatments include impact on cancer risk, impact on glucose… Expand
  • table 1
  • table 3
  • table 4
  • figure 1
Is this relevant?
2016
2016
BackgroundPATRO Children is an ongoing observational, longitudinal, non-interventional, global post-marketing surveillance study… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2013
2013
Objective: To describe the rationale, design and first data from PATRO Children, a postmarketing surveillance of the long-term… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2010
2010
This article discusses the bioequivalence of Omnitrope (Sandoz's rhGH biosimilar) and Genotropin (reference rhGH product… Expand
Is this relevant?